Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.

CONCLUSION: The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice. PMID: 32668484 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32668484?dopt=Abstract

Source: Thrombosis and Haemostasis - July 14, 2020 Category: Hematology Authors: de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, Ginsberg JS, Kruger PC, Chan NC Tags: Thromb Haemost Source Type: research